MECHANISMS OF ACTIONS OF HYDROXYUREA
The principal rationale for treatment with hydroxyurea is its ability to induce HbF (Letvin et al, 1984) . However, hydroxyurea appears to exert its beneficial effects in SCD via a number of additional mechanisms, including modification of red cell-endothelial cell interactions and the rheological properties of HbS-containing red cells and via its myelosuppressive effects, particularly on neutrophils.
HbF production
The increase in HbF induced by hydroxyurea appears to interfere with HbS polymerization both by preventing effective contact between adjacent HbS molecules and also by forming mixed hybrids with HbS that have greater solubility than HbS polymers. However, the exact mechanism by which hydroxyurea induces HbF is still unclear. Unlike several of the other HbF-inducing agents, such as 5-azacytidine and butyrates, hydroxyurea does not appear to directly modulate globin gene expression by altering methylation or binding to transcriptionally active elements. That hydroxyurea is a ribonucleotide reductase inhibitor and arrests cells in S-phase as a result of impairment of DNA replication is well known. It may therefore increase HbF indirectly by killing rapidly dividing late erythroid cells, causing recruitment of more primitive erythroid precursors which in turn produce high levels of HbF, or by acting directly on the primitive precursors thereby stimulating HbF production (Kolata, 1984) . However, even in the early trials, it was clear that induction of HbF was unlikely to explain all the clinical effects of hydroxyurea; treatment was often associated with clinical improvement well before any detectable laboratory rise in HbF and the level of HbF did not always predict response, other variables such as neutrophil counts and mean cell volume (MCV) often being more strongly correlated with reduction in symptoms (Charache et al, 1995) .
Effects of hydroxyurea on red cell-endothelial cell interactions
An important experimental observation is that within 2 weeks of commencing hydroxyurea therapy, prior to any rise in HbF, sickle erythrocytes show reduced adhesion to endothelial cells under low shear flow conditions (Bridges et al, 1996) . Other investigators have shown that hydroxyurea reduces adhesion molecule expression on sickle erythrocytes, including very late activation antigen-4 and CD36 (Styles et al, 1997) . Erythrocytes from hydroxyurea treated patients also show reduced adhesion in vitro to thrombospondin and laminin (Hillery et al, 2000) . As transit times through hypoxic postcapillary venules are critical in promotion of sickling and microvascular occlusion, any reduction in sickle-endothelial adhesion would be predicted to have a beneficial effect.
Effects of hydroxyurea on sickle red cell rheology
Other rheological properties of sickle erythrocytes may also be important, including erythrocyte hydration status and whole cell deformability, both of which can be increased by hydroxyurea (Ballas et al, 1989 ). An animal model of sickle cell disease, the transgenic sickle (SAD) mouse, has been used to investigate these properties further. Hydroxyurea causes increased cellular potassium levels and reduced erythrocyte density. Subsequent exposure to chronic hypoxia led to reduced cellular dehydration compared with untreated animals (de Franceschi et al, 1999) . Human studies have not always shown consistent results with respect to cell hydration, although there appears to be an alteration in the density profile with a reduction in both low-density reticulocytes and high-density sickle cells (Charache et al, 1987; Orringer et al, 1991) .
Myelosuppressive effects of hydroxyurea
Myelosuppressive effects of hydroxyurea may also be important in reduction of symptoms. The fall in neutrophil count appears especially important, and neutrophilia has long been identified as a marker of severity in SCD (Platt et al, 1994) . Neutrophils release powerful pro-inflammatory mediators which are important in endothelial damage and cytokine release, both of which trigger sickling . Neutrophils may also contribute to slow transit time via their adhesive properties and an increase in whole blood viscosity. Evidence that hydroxyurea may modulate neutrophil activation comes from a recent study by Benkerrou et al (2002) , who showed that hydroxyurea treatment in patients with SCD corrected the dysregulated neutrophil L-selectin expression and normalized the increased hydrogen peroxide production characteristic of neutrophil activation in SCD.
Effects of hydroxyurea in SCD: other mechanisms Finally, it has been suggested that hydroxyurea may mediate some of its effects via nitric oxide. Studies in rats showed that metabolism of hydroxyurea leads to nitric oxide release (Jiang et al, 1997) . In humans, nitrosylhaemoglobin can be detected in blood within 30 min of ingestion of hydroxyurea (Glover et al, 1999) and steady state levels of nitric oxide metabolites can be detected in hydroxyurea-treated subjects (Nahavandi et al, 2000 , Gladwin et al, 2002 . This leads to the possibility that some of the clinical effects are mediated by nitric oxide-induced vasodilatation or reduced platelet activation.
CLINICAL EFFICACY OF HYDROXYUREA IN ADULTS WITH SCD
Initial reports of the use of hydroxyurea in SCD emerged in the 1980s (Platt et al, 1984; Veith et al, 1985) . These early studies focused on the ability of hydroxyurea to increase HbF and improve laboratory parameters rather than clinical efficacy. In these studies, using small numbers of patients with homozygous SCD, hydroxyurea consistently led to increases in the number of erythrocytes and reticulocytes containing HbF (F cells and F reticulocytes respectively), in the overall percentage of HbF, and in the MCV. Some studies also showed an increase in steady-state haemoglobin with reductions in neutrophils and reticulocytes, improved red cell survival and improved red cell filterability . These encouraging laboratory changes were accompanied by a lack of evidence of serious toxicity (Charache et al, 1992) and led to the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH) study (Charache et al, 1995) .
The Multicenter Study of Hydroxyurea in Sickle Cell Anemia
This study ran from January 1992 until June 1994 (Charache et al, 1995) . The trial was stopped 10 months early because of a significant reduction in events in the hydroxyurea group. The study was a double-blind, randomized controlled trial of 299 patients with severe SCD (defined as at least three painful crises per year) recruited from 21 centres in the USA and Canada. All patients had HbSS. Treatment was started at a dose of 15 mg ⁄ kg ⁄ d and escalated according to 2 weekly blood counts aiming for the highest dose possible without myelosuppression (maximum tolerated dose; MTD). The results were impressive and included:
• reduced annual rate of crises (2AE5 in the treatment arm vs 4AE5 in the placebo arm) P < 0AE001 • increased median time interval to first crisis (3AE0 vs 1AE5 months) P ¼ 0AE001 • increased median time to second crisis (8AE8 vs 4AE6 months) P < 0AE001 • reduced incidence of acute chest syndrome (25 events vs 51 events) P < 0AE001 • reduced transfusion requirements (48 events vs 73 events) P ¼ 0AE001 The MSH trial showed that hydroxyurea could ameliorate the clinical course of SCD in some adults without serious short-term adverse effects and that the MTD was not always needed to achieve a clinical response. Although higher HbF levels were associated with lower crisis rates, the association was not statistically significant and neutrophil counts appeared to have the most impact, being associated with lower crisis rates throughout the whole study (Charache, 1997) . In addition, the final HbF levels in the hydroxyurea group did not differ markedly from their pretreatment levels (5% vs 9%) (Steinberg et al, 1997a) and overall neither the initial HbF nor the phenotype of the X-linked F-cell production locus (FCP locus) predicted outcome, although the Central African Republic globin haplotype was associated with a reduced response. Use of hydroxyurea was also shown to be cost effective, despite the rigorous monitoring used with 2 weekly clinic visits and blood tests. Average annual costs were $16 810 in the hydroxyurea group vs $22 020 in the placebo group with the vast majority of cost being accounted for by inpatient admissions. This difference failed to reach statistical significance. No account was taken of possible reductions in long-term morbidity with treatment (Moore et al, 2000) . Follow-up data after 6-7 years showed that there had been 51 deaths, 21 in the hydroxyurea group and 30 in the placebo group (P ¼ 0AE13); although because of the unblinding and subsequent switch of many patients to the treatment arm, these data are difficult to interpret. Analysis according to hydroxyurea usage rather than original treatment allocation suggests that the odds ratio for mortality during hydroxyurea use compared with no hydroxyurea use ranges from 0AE59 (P ¼ 0AE08) to 0AE39 (P ¼ 0AE001), depending upon assumptions made about patients with incomplete data. There was no difference in the incidence of stroke in the hydroxyurea-treated patients. None of the patients have developed malignancies and, although the incidence of acute chest syndrome was reduced by hydroxyurea, pulmonary disease was the commonest cause of death (Steinberg et al, 1999) .
Other trials of hydroxyurea in adults with SCD A Cochrane review looking at the use of hydroxyurea in SCD was published in February 2001 (Davies & Olujohungbe 2001) . Twenty randomized or quasi-randomized trials comparing hydroxyurea with placebo, standard therapy or other interventions were found. Only two of these, the MSH study and the Belgian paediatric trial (see below), were assessable. Problems with study design or data excluded the other 18. Despite these methodological concerns, none of the published data conflict in any substantive way with the MSH findings. The vast majority report increases in HbF, MCV and steady-state haemoglobin along with clinical improvement in the number of painful crises, hospital attendance rates and acute chest syndrome (el-Hazmi et al, 1992; Kutlar et al, 2000) . Studies from the developing world suggested hydroxyurea was no less effective in these populations (Lima et al, 1997; el-Alfy 2000) .
While these studies have been useful in establishing the clinical effectiveness of hydroxyurea, they leave a number of unanswered questions including: the optimum dose and schedule, the potential for prospective identification of responders and non-responders to avoid exposure to a potentially toxic drug, the impact of treatment on long-term organ damage, morbidity and mortality, and the safety of hydroxyurea in children. A registry of European patients on hydroxyurea has recently been established with the aim of addressing these important questions (Davies & RobertsHarwood, 1998 ).
Hydroxyurea and stroke in adults with SCD Hydroxyurea has many theoretical benefits in the treatment and prevention of stroke. It lowers white cell count, improves steady-state haemoglobin and reduces the risk of acute chest syndrome: all risk factors for stroke (OheneFrempong et al, 1998) . It also leads to improved rheological properties of red cells and reduction in endothelial adhesion. The only theoretical disadvantage is the increased whole blood viscosity secondary to the rise in steady-state haemoglobin. Despite these promising properties, the MSH study did not show a statistical reduction in stroke although the numbers involved (two in treatment group and three in placebo) were very small (Charache et al, 1995) . It is possible that hydroxyurea may have a role to play in patients coming off transfusion regimes, although preliminary data in children suggest that this may be associated with a significant risk of stroke recurrence . However, as most patients are unwilling or unable to continue transfusions lifelong, many clinicians recommend stopping transfusions once patients reach adulthood (Powars, 2000) . Prospective randomized trials of hydroxyurea versus continuing transfusions will be required to define the role of hydroxyurea in this setting.
HYDROXYUREA IN CHILDREN
The use of hydroxyurea in children potentially brings the greatest rewards in terms of prevention of end organ damage but also carries greater potential risks (Vichinsky, 1997) . The possibility of adverse effects on growth and development, and the risks of secondary malignancy in groups exposed to the drug for long periods led to caution. However, a number of promising phase I ⁄ II studies, showing profound and sustained increases in HbF without serious adverse events, led to larger scale trials (Scott et al, 1996; Kinney et al, 1999) . The published studies of hydroxyurea therapy in children with SCD are summarized in Table II .
Evidence of efficacy
Of the published studies, only four have focused on measures of clinical improvement in the severity of SCD (Ferster et al, 1996 (Ferster et al, , 2001 Jayabose et al, 1996; Koren et al, 1999) while the other studies have mainly assessed laboratory parameters of response and safety. The Belgian paediatric trial of hydroxyurea in severe SCD first reported in 1996 (Ferster et al, 1996) , with the 5-year follow-up in 2001 (Ferster et al, 2001 ). The first study included 25 children (mean age 9 years) in a single-blind crossover design with 6 months hydroxyurea (20-25 mg ⁄ kg ⁄ d) and 6 months placebo. The follow-up study described 93 patients (median age 7 years), including a small number of adults, who had a median follow-up of 3AE5 years. There was evidence in both studies of a reduction in hospital admissions and days spent in hospital, and evidence of a reduced frequency of acute chest syndrome. Significant increases in HbF and MCV with reduction in white cell and reticulocyte counts were also seen. MTD was not needed for efficacy and no important adverse events were noted. Similar beneficial results with hydroxyurea have been reported in the other clinical studies in children (Jayabose et al, 1996; Koren et al, 1999) . In all the studies to date, growth and development appear to be unaffected (Rogers, 1997; Wang et al, 2002) even in children under school age (Hoppe et al, 2000) and in infants (Wang et al, 2001) . However, there is no evidence that hydroxyurea prevents stroke or the recurrence of stroke in children. The largest study included 16 children, three of whom suffered a recurrent stroke within 16 weeks of changing from regular transfusions to hydroxyurea, although the dose and duration of hydroxyurea therapy may have contributed to these worrying results .
Use of hydroxyurea in very young children to prevent organ dysfunction
The development of end organ damage is closely associated with morbidity and mortality in SCD (Platt et al, 1994) . This damage often starts early with evidence of splenic dysfunction by 6 months of age. This raises the possibility that hydroxyurea might be able to exert a significant diseasemodifying effect if given to very young children with SCD. An early report suggested that hydroxyurea use in two young adults with sickle cell disease had led to reversal of splenic dysfunction (Claster & Vichinsky, 1996) . This was not confirmed by a trial in older children (12 ± 1AE2 years) perhaps because splenic auto-infarction may well have occurred by this age (Olivieri & Vichinsky, 1998) . However, in a 2-year pilot trial of hydroxyurea (20 mg ⁄ kg ⁄ d) in 28 children aged 6-28 months (median 15 months) with HbSS and Sb°thalassaemia, Wang et al (2001) reported a lower frequency of functional asplenia (47%) compared with the expected frequency from historical data of 80% as assessed by radionucleotide scanning. While this may indicate a clinical benefit of hydroxyurea in very young children with SCD, this study also showed that hydroxyurea is clearly not enough on its own to completely prevent the major complications of the disease at this age. Two of the 28 children in this study had neurological events, three had acute chest syndrome and two had splenic sequestration despite hydroxyurea treatment. These results emphasize the still considerable uncertainty as to its role in young children; a randomized controlled trial would seem warranted.
DOSE AND MONITORING OF HYDROXYUREA
The dose of hydroxyurea needed for maximal clinical benefit appears not to be the same as the MTD. Although dose-dependent myelosuppression is rarely associated with adverse clinical events in the form of invasive infection or bleeding, it seems prudent to minimize doses to reduce the risk of long-term toxicity, including secondary Jayabose et al (1996) malignancies. Hydroxyurea is available as capsules of 500 mg and syrup can be made up for paediatric use (generally 100 mg ⁄ ml) but is not widely available commercially. The MSH study started patients at 10-15 mg ⁄ kg once daily. Blood tests for full blood count, renal and liver function, along with HbF level were taken every 2 weeks. The dose was increased by 5 mg ⁄ kg ⁄ d every 12 weeks in the absence of bone marrow suppression (neutrophil count < 2 · 10 9 ⁄ l, haemoglobin < 4AE5 g ⁄ dl, reticulocytes or platelets < 80 · 10 9 ⁄ l). Once bone marrow suppression had occurred, the dose was restarted at 2AE5 mg ⁄ kg ⁄ d less than the toxic dose and this was defined as the MTD. Most patients achieved a dose of 20-25 mg ⁄ kg ⁄ d although some tolerated 35 mg ⁄ kg ⁄ d. Some patients, however, showed toxicity at levels of only 2AE5 mg ⁄ kg ⁄ d.
Most studies in children have used doses of approximately 20 mg ⁄ kg ⁄ d. Unfortunately, there have been few studies looking at alternative dosing regimes. In general, our practice is to start at a dose of 15-20 mg ⁄ kg ⁄ d. Full blood count (FBC), including reticulocytes, HbF level, renal and liver function tests, are performed prior to commencing treatment. FBC and reticulocytes should be repeated at 2 weeks and then at 2-4 week intervals during the initial phases of treatment. Renal and liver function should be checked at least monthly. Once the patient is well established on a stable dose, monthly blood counts should suffice. The interval between counts should never exceed 6 weeks. Caution should be taken in issuing repeat prescriptions without a recent blood count and supply should probably not exceed 4-6 weeks worth at any one time. Patients are asked to report any fever, sore mouth or other worrying symptoms and have a blood count done in these circumstances. When monitoring the response to hydroxyurea, the effect on clinical well-being is probably more important than any absolute increase in HbF levels. Patients that fail to respond clinically to 20 mg ⁄ kg ⁄ d can have their dose escalated as long as there is no evidence of marrow suppression.
Although most cases of poor response are due to compliance (Steinberg et al, 1997a) , there appear to be some individuals who are biologically resistant to hydroxyurea (Yang et al, 1997) . Addition of erythropoietin has helped in a small number of cases (el-Hazmi et al, 1995) . Because of concerns about long-term toxicity, it is probably wise to withdraw treatment in any patient who has had no clinical or haematological response after a trial of 3-6 months of treatment. It is worth noting that laboratory methods for measurement of HbF have generally been developed to measure fairly low levels. It is important to ensure that the method used is reliable at higher HbF concentrations (Epstein et al, 1996; Schultz, 1999) .
LONG-TERM TOXICITY AND SAFETY OF HYDROXYUREA

Myelosuppression
The commonest side-effect is dose-dependent myelosuppression. Although this is usually transient, there have been occasional reports of aplasia lasting several weeks or months (Vichinsky & Lubin, 1994) . As far as we are aware, there has never been a documented episode of lifethreatening infection associated with hydroxyurea-induced neutropenia.
Skin, gastrointestinal and renal Cutaneous side-effects include nail hyperpigmentation, which is common, and increased skin pigmentation, especially on the palms and soles (O'Branski et al, 2001) . Patients should be warned of this potential side-effect as it can be quite distressing. Hydroxyurea is associated with development of leg ulcers in myeloproliferative diseases and some studies have quoted rates of up to 30% in SCD patients on hydroxyurea, but the role of hydroxyurea is unclear as 90% of these patients had a prior history of ulcers (Chaine et al, 2001 ). In the MSH study, 32% of patients had leg ulcers at enrolment and new ulcers developed with equal frequency in treatment and placebo groups (Charache et al, 1995) . Nausea, rash and other gastrointestinal upsets have been described with hydroxyurea (de Montalembert et al, 1999) but, in randomized trials, are no commoner than with placebo (Charache et al, 1995) . Hydroxyurea is renally excreted and small increases in creatinine are sometimes seen on treatment. Renal function should be monitored; dose reductions are needed in patients with renal failure.
Pregnancy and teratogenicity
Studies in rats showed an increase in post-implantation losses, and reduced fetal and placental weights (Spencer et al, 2000) . Despite strict instructions to take contraceptive precautions for both men and women patients on treatment, there have been a number of pregnancies in published studies. More than 14 cases have now been described: three pregnancies were terminated electively, one infant was stillborn in a mother with eclampsia and the other 10 resulted in healthy live-born infants with no congenital abnormalities (Byrd et al, 1999) . Patients on hydroxyurea should be advised as to the theoretical risks of pregnancy and those wishing to conceive should stop treatment 3-6 months before switching to unprotected intercourse.
Malignancy
The Polycythemia Study Group showed a trend towards increased second malignancies after 8 years in a small study of 51 patients treated with hydroxyurea (9AE8% vs 3AE7% in historical control group; P ¼ 0AE1) (Fruchtman et al, 1997) . A larger study of 150 patients with polycythaemia rubra vera diagnosed before the age of 65 showed an actuarial risk of leukaemia of about 10% by the 13th year of treatment and a 15% rate of other cancers, although this was only slightly greater than the expected rate of 11AE5% in patients of this age group (Najean & Rain, 1997) . A more suitable comparison group might be young patients with erythrocytosis secondary to inoperable congenital heart disease; a study of 64 patients treated with hydroxyurea for 2-15 years showed no increase in malignancy (Triadou et al, 1994) . Initial pilot studies of hydroxyurea showed that some adults had pre-existing chromosomal breaks in peripheral blood leucocytes but there was no progression through treatment and no difference from HbSS and HbAA controls (Charache et al, 1987) . More worrying are experimental studies of acquired DNA mutations in children treated for between 7 and 30 months that showed an increased mutation rate as measured by the VDJ recombination assay. Although this was significantly greater than with control children (P ¼ 0AE04), it was still within the normal range for age (Hanft et al, 2000) .
There have now been four reported cases of malignancy in sickle cell patients on hydroxyurea (Table III) . Patients 1 and 4 are likely to be unrelated to treatment, given the time course and type of malignancy. Cases 2 and 3 are more doubtful. It is difficult to judge risk as the denominator in terms of total number of sickle cell patients on hydroxyurea is unknown. The earliest large-scale recruitment to trials began in 1992 so we have now accumulated 10 years worth of experience. The risk appears small but continued caution is needed (Ho & Murgo, 1995; Silver, 1995; de Montalembert & Davies 2001 ).
HYDROXYUREA FOR SICKLING DISORDERS OTHER THAN HBSS
Initial studies were confined to patients with homozygous sickle cell disease. Smaller scale studies have confirmed similar advantages of treatment in other sickling conditions especially sickle b-thalassaemia (Voskaridou et al, 1995; Loukopoulos et al, 2000; Rigano et al, 2001) . Theoretically hydroxyurea may be even more effective in this group of disorders than in HbSS as HbF production has the added advantage of Ômopping upÕ excess a-chains responsible for some of the ineffective erythropoiesis. Results in HbSC disease are more difficult to interpret. An initial study of six patients showed an increase in haemoglobin levels and MCV, and a decrease in reticulocytes and bilirubin on treatment but no statistically significant change in HbF levels (Steinberg et al, 1997b) . A more recent trial in six children with HbSC showed a significant rise in HbF and a good clinical response with a marked reduction in hospital admission rates (Miller et al, 2001) . It is unlikely that these patients are intrinsically resistant to hydroxyurea and therefore there seems no reason to deny severely affected individuals a trial of therapy. Case reports documenting beneficial effects of hydroxyurea in HbSD-Punjab and HbSOArab disease can also be found (Rogers, 1997; Udden et al, 1999) .
CONCLUSIONS
Based on the evidence reviewed above, hydroxyurea plays an important role in the management of a number of complications of SCD. This is summarized in Table IV . Recurrent vaso-occlusive crises For the majority of adults with SCD, hydroxyurea can be recommended as the treatment of choice for preventing vaso-occlusive crises in patients who have frequent, debilitating vaso-occlusive crises especially where these lead to ‡ 3 hospital admissions per year or to excessive time lost from work or higher education. Close monitoring for toxicity is essential and this, or worries about possible long-term toxicity, may lead many patients to decline this option. Unfortunately, there are as yet no other pharmacological agents available with equivalent efficacy and the risks associated with chronic transfusion make this an unattractive approach for vaso-occlusive crises. For children with recurrent painful crises, every attempt should be made to educate and support the family about the best ways to prevent and cope with recurrent crises, as this will often be sufficient to reduce the frequency of hospital admissions.
Psychologists with special expertise in SCD are often very valuable in more severe cases. Hydroxyurea should be reserved for children who have ongoing problems even after these intensive supportive measures have been explored.
Recurrent acute chest syndrome
Given the mortality and morbidity associated with acute chest syndrome in SCD and the clear cut evidence of a reduced incidence of acute chest syndrome in patients on hydroxyurea, this should be the treatment of choice to prevent recurrence for all patients, adults and children, who have suffered more than one episode of acute chest syndrome in the preceding 1-2 years. There is no evidence of benefit of transfusion in this setting and stem cell transplantation should be reserved for children who have failed to respond to, or are unable to take, hydroxyurea.
Other SCD-related complications There is no evidence yet that hydroxyurea is able to prevent first or recurrent strokes, splenic ⁄ hepatic sequestration, priapism, osteonecrosis, or leg ulcers. It is also unclear whether hydroxyurea given early in life is able to preserve splenic function. Given the known and possible toxicity of hydroxyurea, its use in these complications of SCD should be investigated within the context of controlled clinical studies.
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